877399-52-5 Crizotinib manufacturer CAS NO.877399-52-5

FOB Price: USD: 3.00-3.00 /Kilogram Get Latest Price
Min.Order: 1 Kilogram
Payment Terms: D/A,D/P,T/T
Available Specifications:
pharmaceutical grade(0-1000)Kilogram3/Kilogram0USD

Product Details

Keywords

877399-52-5 Crizotinib in stock
Supply 877399-52-5 Crizotinib
877399-52-5 Crizotinib manufacturer

Quick Details

ProName: 877399-52-5 Crizotinib manufacturer
CasNo: 877399-52-5
Molecular Formula: C8H6BrClNO4P.C7H9N
Appearance: white powder
Application: API,or Intermediates,fine chemicals
DeliveryTime: from stock
PackAge: 25kg/drum,or as per customers'demand
Port: shanghai or hangzhou or other china po...
ProductionCapacity: 100 Metric Ton/Year
Purity: 98%min
Storage: dry and cool
Transportation: air,sea,courier
LimitNum: 1 Kilogram
Moisture Content: <0.1%
Impurity: less than 0.2%
heavy metals: less than 20ppm

Superiority

GIHI CHEMICALS exported this product to many countries and regions at best price. if you are looking for the material's manufacturer or supplier in china, GIHI CHEMICALS is your best choice. pls contact with us freely for getting detailed product specifications, product tech. date sheet, coa and msds, prices, delivery time and payment terms. as a leading manufacturer and supplier of chemicals in china, GIHI CHEMICALS not only supply popular chemicals, but also GIHI CHEMICALS's r&d center offer custom synthesis services. GIHI CHEMICALS can provide different quantities of custom synthesis chemicals in lab, plant and industrial.

Identification
Name		Crizotinib
Synonyms		PF-02341066; 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]pyridin-2-amine; PF 2341066

Molecular Structure

Molecular Formula		C₂₁H₂₂Cl₂FN₅O
Molecular Weight		450.34
CAS Registry Number		877399-52-5

Details

GIHI CHEMICALS, dedicated to the development, production and marketing of chemicals. we are a leading manufacturer and supplier of chemicals in china.

manufacturing base: the company has some manufacturing base in zhejiang, jiangsu and shandong provide. these bases focus on production and contract manufacturing.

strong quality control system: strength of our ethical commitment to quality control and quality assurance systems firmly based on iso standard. qa and qc used in the whole process of raw material control, process control and finished product quality inspection.

Quality Cooperation：GIHI CHEMICALS has established very good cooperation and business relations with hundreds of chinese qualified manufacturers by long time business intercourse.

rich experience in sales: our customers throughout the world, especially the world-renowned companies, such as bachem, basf, celanese, corden,dow,evonik, genzyme,henkel, merck,roche,sanofi,solvay.

Crizotinib Basic information
Biological Activity side effects href="javascript:void(0);"/a>
side effects	crizotinib (Xalkori) is an oral receptor tyrosine kinase inhibitor indicated for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). Common side effects with Xalkori use include upper respiratory infection, nausea, vomiting, stomach pain, decreased appetite, insomnia, dizziness, tired feeling, diarrhea, constipation, rash or itching, cold symptoms (stuffy nose, sneezing, sore throat), numbness or tingling, or swelling in your hands or feet. #
FDA Approves Crizotinib Capsules	On March 11, 2016, the U. S. Food and Drug Administration approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. Crizotinib was first approved in 2011 for the treatment of patients whose tumors are anaplastic lymphoma kinase (ALK)-positive. The current approval was based on a multicenter, single-arm trial in patients with metastatic ROS1 rearrangement-positive NSCLC. All patients received crizotinib 250 mg orally twice daily. The efficacy outcome measures were objective response rate (ORR) according to RECIST v1.0 as evaluated by an independent radiology review (IRR) and as evaluated by the investigators. Duration of response (DoR) was an additional outcome measure. The trial enrolled 50 patients with an age range of 25-77 years whose tumors were prospectively determined to be ROS1-positive by fluorescence in situ hybridization (FISH; 96%) or reverse transcription polymerase chain reaction (RT-PCR; 4%) clinical trial assays. The ORR by IRR was 66% (95% CI: 51%, 79%) with a median DoR of 18 months. The ORR according to investigators was 72% (95% CI: 58%, 84%). The safety results of this trial were generally consistent with the safety profile of crizotinib evaluated in 1,669 patients with ALK-positive metastatic NSCLC. The most common adverse reactions of Xalkori are vision disorders, nausea, diarrhea, vomiting, edema, constipation, elevated transaminases, fatigue, decreased appetite, upper respiratory infection, dizziness, and neuropathy. The recommended dose and schedule for crizotinib is 250 mg capsules taken by mouth twice daily. #
Chemical Properties	White Solid
Uses	A potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). A potential antitumor agent.
Uses	Crizotinib is a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent.
Uses	PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley

flexible payment terms: various payment terms such as l/c,d/p,d/a and t/t will be accepted. special notice: GIHI CHEMICALS never require customers to remit payment to a personal account. beware of being cheated